Ipilimumab monotherapy or the combined therapy of anti-CTLA-4 and anti-PD-1 resulted in the highest risk of polyendocrinopathies, including PAI, followed by anti-PD-1 monotherapy, which was consistent with other researchers [13]. The gene discussed is CTLA4; the disease is polyendocrinopathy.